Optimas Capital’s BioNTech BNTX Stock Holding History

Optimas Capital’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-8,400	Closed	-$998K	–	28
2024 Q3	$998K	Buy	+8,400	New	+$772K	0.95%	22
2022 Q2	–	Sell	-6,000	Closed	-$1.02M	–	23
2022 Q1	$1.02M	Buy	+6,000	New	+$1.01M	0.96%	22

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Optimas Capital's BNTX Position: Q4 2024 in Review

Optimas Capital sold out of BioNTech (BNTX) in Q4 2024, closing a stake of 8,400 shares — an estimated $998K sold.

Optimas Capital first reported a position in BNTX in Q1 2022 and held it in 2 quarters. The position peaked at $1.02M in Q1 2022. 303 funds tracked by Wall St. Rank hold BNTX as of Q4 2024.

Optimas Capital reported no remaining BioNTech position as of Q4 2024 after selling out during the quarter.
Optimas Capital sold 8,400 BioNTech shares in Q4 2024, an estimated $998K.
Optimas Capital first reported a position in BioNTech in Q1 2022 and held it in 2 quarters.
Optimas Capital's BioNTech position peaked at $1.02M in Q1 2022.
303 funds tracked by Wall St. Rank held BioNTech as of Q4 2024.

Based on Optimas Capital's 13F filing for Q4 2024, filed 11 Feb 2025.